As part of the G-Rex Grant, the Gates Institute will also receive early access to CellReady's G-CAR-TTM, a standardized CAR-T drug product manufacturing operation conceived of by CellReady, the world's first and only G-Rex CDMO. G-CAR-TTM is ideal for high-throughput, low-cost manufacturing. ScaleReady's G-Rex Grant Program has authorized over $40M of products at no cost to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Indiv ...